CA2879399C - Dispositifs et procedes de detection et d'identification ameliorees de maladies - Google Patents
Dispositifs et procedes de detection et d'identification ameliorees de maladies Download PDFInfo
- Publication number
- CA2879399C CA2879399C CA2879399A CA2879399A CA2879399C CA 2879399 C CA2879399 C CA 2879399C CA 2879399 A CA2879399 A CA 2879399A CA 2879399 A CA2879399 A CA 2879399A CA 2879399 C CA2879399 C CA 2879399C
- Authority
- CA
- Canada
- Prior art keywords
- bio
- electro
- chemical
- micro
- optical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 204
- 238000000034 method Methods 0.000 title claims abstract description 46
- 201000010099 disease Diseases 0.000 title claims description 53
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 53
- 239000000126 substance Substances 0.000 claims abstract description 199
- 239000000654 additive Substances 0.000 claims abstract description 139
- 230000000996 additive effect Effects 0.000 claims abstract description 80
- 239000012620 biological material Substances 0.000 claims abstract description 65
- 230000035945 sensitivity Effects 0.000 claims abstract description 64
- 238000002203 pretreatment Methods 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 142
- 201000011510 cancer Diseases 0.000 claims description 123
- 230000003287 optical effect Effects 0.000 claims description 71
- 210000004027 cell Anatomy 0.000 claims description 63
- 238000006243 chemical reaction Methods 0.000 claims description 63
- 229910052760 oxygen Inorganic materials 0.000 claims description 56
- 239000001301 oxygen Substances 0.000 claims description 56
- 239000012472 biological sample Substances 0.000 claims description 53
- 230000004044 response Effects 0.000 claims description 52
- 102000004190 Enzymes Human genes 0.000 claims description 47
- 108090000790 Enzymes Proteins 0.000 claims description 47
- 239000000523 sample Substances 0.000 claims description 46
- 239000000090 biomarker Substances 0.000 claims description 42
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 35
- 239000003054 catalyst Substances 0.000 claims description 31
- 239000007800 oxidant agent Substances 0.000 claims description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 29
- 238000009826 distribution Methods 0.000 claims description 28
- 230000002285 radioactive effect Effects 0.000 claims description 25
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 24
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 23
- 238000010521 absorption reaction Methods 0.000 claims description 22
- 150000002500 ions Chemical class 0.000 claims description 22
- 235000018102 proteins Nutrition 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 238000005259 measurement Methods 0.000 claims description 21
- 239000006193 liquid solution Substances 0.000 claims description 20
- 239000003638 chemical reducing agent Substances 0.000 claims description 19
- 230000005684 electric field Effects 0.000 claims description 19
- -1 glucose compound Chemical class 0.000 claims description 19
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 18
- 230000004071 biological effect Effects 0.000 claims description 18
- 239000003623 enhancer Substances 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 14
- 238000005842 biochemical reaction Methods 0.000 claims description 14
- 201000007270 liver cancer Diseases 0.000 claims description 14
- 208000014018 liver neoplasm Diseases 0.000 claims description 14
- 230000009102 absorption Effects 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 13
- 229910052708 sodium Inorganic materials 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 12
- 206010033128 Ovarian cancer Diseases 0.000 claims description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
- 230000003197 catalytic effect Effects 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 230000001590 oxidative effect Effects 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 10
- 235000011054 acetic acid Nutrition 0.000 claims description 10
- 210000000349 chromosome Anatomy 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 230000000704 physical effect Effects 0.000 claims description 10
- 229910052700 potassium Inorganic materials 0.000 claims description 10
- 230000000284 resting effect Effects 0.000 claims description 10
- 108091035539 telomere Proteins 0.000 claims description 10
- 210000003411 telomere Anatomy 0.000 claims description 10
- 102000055501 telomere Human genes 0.000 claims description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 230000000975 bioactive effect Effects 0.000 claims description 9
- 230000005540 biological transmission Effects 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 238000003487 electrochemical reaction Methods 0.000 claims description 9
- 239000003792 electrolyte Substances 0.000 claims description 9
- 239000011737 fluorine Substances 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 9
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 9
- 230000036284 oxygen consumption Effects 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 9
- 230000036632 reaction speed Effects 0.000 claims description 9
- 238000001228 spectrum Methods 0.000 claims description 9
- 230000003068 static effect Effects 0.000 claims description 9
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 claims description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 8
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims description 8
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 8
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 230000004069 differentiation Effects 0.000 claims description 8
- 230000006870 function Effects 0.000 claims description 8
- 229940076788 pyruvate Drugs 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052802 copper Inorganic materials 0.000 claims description 7
- 239000010949 copper Substances 0.000 claims description 7
- 239000007789 gas Substances 0.000 claims description 7
- 239000002105 nanoparticle Substances 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 claims description 6
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003150 biochemical marker Substances 0.000 claims description 6
- 229910017052 cobalt Inorganic materials 0.000 claims description 6
- 239000010941 cobalt Substances 0.000 claims description 6
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 6
- 239000003086 colorant Substances 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 6
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 6
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 229910052750 molybdenum Inorganic materials 0.000 claims description 6
- 239000011733 molybdenum Substances 0.000 claims description 6
- 235000006408 oxalic acid Nutrition 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- 229910052711 selenium Inorganic materials 0.000 claims description 6
- 239000011669 selenium Substances 0.000 claims description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 239000011593 sulfur Substances 0.000 claims description 6
- 239000011701 zinc Substances 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 239000012286 potassium permanganate Substances 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 229910001446 Cu2+ Inorganic materials 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 229910002651 NO3 Inorganic materials 0.000 claims description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910001919 chlorite Inorganic materials 0.000 claims description 4
- 229910052619 chlorite group Inorganic materials 0.000 claims description 4
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 150000002366 halogen compounds Chemical class 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 229910017604 nitric acid Inorganic materials 0.000 claims description 4
- 239000001272 nitrous oxide Substances 0.000 claims description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 4
- 150000004968 peroxymonosulfuric acids Chemical class 0.000 claims description 4
- 229960001922 sodium perborate Drugs 0.000 claims description 4
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- IDONYDPAVSCVFZ-UHFFFAOYSA-N 2-oxopropanoic acid;hydrobromide Chemical compound Br.CC(=O)C(O)=O IDONYDPAVSCVFZ-UHFFFAOYSA-N 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 229910000497 Amalgam Inorganic materials 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 239000012031 Tollens' reagent Substances 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 3
- 150000001845 chromium compounds Chemical class 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000011981 lindlar catalyst Substances 0.000 claims description 3
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 claims description 3
- YVUZUKYBUMROPQ-UHFFFAOYSA-N mercury zinc Chemical compound [Zn].[Hg] YVUZUKYBUMROPQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000012285 osmium tetroxide Substances 0.000 claims description 3
- 229910000489 osmium tetroxide Inorganic materials 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 150000002978 peroxides Chemical class 0.000 claims description 3
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical class O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 claims description 3
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 claims description 3
- 235000019260 propionic acid Nutrition 0.000 claims description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 229910001023 sodium amalgam Inorganic materials 0.000 claims description 3
- 239000012279 sodium borohydride Substances 0.000 claims description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 3
- 229940054269 sodium pyruvate Drugs 0.000 claims description 3
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 2
- 102000005548 Hexokinase Human genes 0.000 claims 1
- 108700040460 Hexokinases Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000002699 waste material Substances 0.000 claims 1
- 239000010796 biological waste Substances 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 description 22
- 239000000463 material Substances 0.000 description 16
- 238000003745 diagnosis Methods 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 238000012544 monitoring process Methods 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 6
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 150000002902 organometallic compounds Chemical group 0.000 description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000006555 catalytic reaction Methods 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- NPDACUSDTOMAMK-UHFFFAOYSA-N 4-Chlorotoluene Chemical compound CC1=CC=C(Cl)C=C1 NPDACUSDTOMAMK-UHFFFAOYSA-N 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 229910052804 chromium Inorganic materials 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 3
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000004157 Hydrolases Human genes 0.000 description 3
- 108090000604 Hydrolases Proteins 0.000 description 3
- 102000004195 Isomerases Human genes 0.000 description 3
- 108090000769 Isomerases Proteins 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 102000004317 Lyases Human genes 0.000 description 3
- 108090000856 Lyases Proteins 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108010053763 Pyruvate Carboxylase Proteins 0.000 description 3
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 108010066830 dimethyl sulfoxide reductase Proteins 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 229910001961 silver nitrate Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- KCNIMEJTKUGMLA-UHFFFAOYSA-N 2-iodo-2-methylpentane Chemical compound CCCC(C)(C)I KCNIMEJTKUGMLA-UHFFFAOYSA-N 0.000 description 2
- NTIGNJOEVBTPJJ-UHFFFAOYSA-N 3,3-dibromopentane Chemical compound CCC(Br)(Br)CC NTIGNJOEVBTPJJ-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- XGQGTPFASZJKCD-UHFFFAOYSA-N fluorocyclopentane Chemical compound FC1[CH]CCC1 XGQGTPFASZJKCD-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Chemical compound Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 description 2
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 description 2
- GEOVEUCEIQCBKH-UHFFFAOYSA-N hypoiodous acid Chemical compound IO GEOVEUCEIQCBKH-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 125000000962 organic group Chemical group 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- WTXXSZUATXIAJO-OWBHPGMISA-N (Z)-14-methylpentadec-2-enoic acid Chemical compound CC(CCCCCCCCCC\C=C/C(=O)O)C WTXXSZUATXIAJO-OWBHPGMISA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241001296119 Panteles Species 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- JOPOVCBBYLSVDA-UHFFFAOYSA-N chromium(6+) Chemical class [Cr+6] JOPOVCBBYLSVDA-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000027734 detection of oxygen Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052809 inorganic oxide Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000002032 lab-on-a-chip Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000004717 pyruvic acids Chemical class 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000009834 selective interaction Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000010944 silver (metal) Substances 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/10—Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0832—Geometry, shape and general structure cylindrical, tube shaped
- B01L2300/0838—Capillaries
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0867—Multiple inlets and one sample wells, e.g. mixing, dilution
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physiology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention porte sur des micro-dispositifs et des procédés de leur utilisation pour détection au niveau microscopique d'une propriété d'une matière biologique contenue dans un liquide ou existant à l'état liquide. Le dispositif comprend un orifice d'admission (0212, 0322) de la matière biologique pour permettre son entrée dans le micro-dispositif, une unité de prétraitement facultative, une unité de sondage (0325), une unité de détection (0326), un contrôleur de système et une sortie (0213, 0323) pour la matière biologique résiduelle ou des déchets à expulser du micro-dispositif. Le micro-dispositif peut comporter au moins un additif chimique, biologique ou biochimique (0422) conjointement avec le micro-dispositif pour améliorer une sensibilité et une spécificité de détection.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261672231P | 2012-07-16 | 2012-07-16 | |
| US61/672,231 | 2012-07-16 | ||
| PCT/CN2013/000852 WO2014012356A1 (fr) | 2012-07-16 | 2013-07-16 | Dispositifs et procédés de détection et d'identification améliorées de maladies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2879399A1 CA2879399A1 (fr) | 2014-01-23 |
| CA2879399C true CA2879399C (fr) | 2019-03-26 |
Family
ID=49948219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2879399A Active CA2879399C (fr) | 2012-07-16 | 2013-07-16 | Dispositifs et procedes de detection et d'identification ameliorees de maladies |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20150198586A1 (fr) |
| EP (1) | EP2872887A4 (fr) |
| CN (1) | CN104508480B (fr) |
| CA (1) | CA2879399C (fr) |
| TW (3) | TWI630385B (fr) |
| WO (1) | WO2014012356A1 (fr) |
| ZA (1) | ZA201500295B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9645010B2 (en) | 2009-03-10 | 2017-05-09 | The Regents Of The University Of California | Fluidic flow cytometry devices and methods |
| US9134221B2 (en) | 2009-03-10 | 2015-09-15 | The Regents Of The University Of California | Fluidic flow cytometry devices and particle sensing based on signal-encoding |
| WO2012054904A2 (fr) | 2010-10-21 | 2012-04-26 | The Regents Of The University Of California | Dispositifs microfluidiques avec circuits électroniques alimentés par une liaison sans fil |
| CN105008895B (zh) | 2012-10-15 | 2019-02-15 | 纳诺赛莱克特生物医药股份有限公司 | 颗粒分选的系统、设备和方法 |
| US10012642B2 (en) * | 2013-03-15 | 2018-07-03 | Anpac Bio-Medical Science (Lishui) Co., Ltd. | Methods and apparatus for enhanced detection of diseases |
| WO2015200145A1 (fr) * | 2014-06-27 | 2015-12-30 | Coherence Apps, Llc | Systèmes et procédés pour délivrer des fréquences de remèdes |
| DE102016203576A1 (de) * | 2016-03-04 | 2017-09-07 | Hamilton Bonaduz Ag | Verfahren zur Kalibration von impedanzspektroskopischen Biomassesensoren und Verwendung einer Suspension zur Durchführung eines solchen Verfahrens |
| CN107844657B (zh) * | 2017-11-15 | 2020-04-10 | 清华大学 | 氧化锌压敏电阻微观特性模拟优化计算模型 |
| TWI666445B (zh) * | 2018-07-26 | 2019-07-21 | 緯創資通股份有限公司 | 檢測裝置及其檢測盒組 |
| CN110018159A (zh) * | 2019-05-08 | 2019-07-16 | 衢州超越环保科技有限公司 | 一种城市雨水ph检测及管理利用系统 |
| TWI743829B (zh) * | 2019-09-11 | 2021-10-21 | 筑波醫電股份有限公司 | 眼球檢體測量裝置及眼球檢體檢測方法 |
| CN111079579B (zh) * | 2019-12-02 | 2023-07-25 | 英华达（上海）科技有限公司 | 细胞图像的识别方法、装置以及系统 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02504188A (ja) * | 1987-07-02 | 1990-11-29 | イン・ヴィトロ・テクノロジーズ・インコーポレイテッド | 複数分析の免疫検定用毛細管装置 |
| EP0781997A1 (fr) * | 1995-12-27 | 1997-07-02 | FUJIREBIO Inc. | Instrument pour essais immunologiques simplifiés et méthode d'essais immunologiques simplifiée en utilisant l'instrument |
| US6092530A (en) | 1999-03-24 | 2000-07-25 | The B.F. Goodrich Company | Remotely interrogated implant device with sensor for detecting accretion of biological matter |
| US6613580B1 (en) * | 1999-07-06 | 2003-09-02 | Caliper Technologies Corp. | Microfluidic systems and methods for determining modulator kinetics |
| US7811768B2 (en) | 2001-01-26 | 2010-10-12 | Aviva Biosciences Corporation | Microdevice containing photorecognizable coding patterns and methods of using and producing the same |
| US6922118B2 (en) | 2002-11-01 | 2005-07-26 | Hrl Laboratories, Llc | Micro electrical mechanical system (MEMS) tuning using focused ion beams |
| EP1561507A1 (fr) * | 2004-01-27 | 2005-08-10 | Future Diagnostics B.V. | Système pour caractériser un fluide, dispositif microfluidique pour caractériser ou analyser les composants de concentrations, une méthode de caractériser ou d'analyser de telles concentrations et un dispositif de mesure |
| US20080274450A1 (en) * | 2005-12-23 | 2008-11-06 | Alvitae Pharmaceuticals | Methods and applications of molecular beacon imaging for identifying and validating genomic targets, and for drug screening |
| US20100137163A1 (en) * | 2006-01-11 | 2010-06-03 | Link Darren R | Microfluidic Devices and Methods of Use in The Formation and Control of Nanoreactors |
| US7807454B2 (en) * | 2006-10-18 | 2010-10-05 | The Regents Of The University Of California | Microfluidic magnetophoretic device and methods for using the same |
| WO2009018467A2 (fr) * | 2007-07-31 | 2009-02-05 | Massachusetts Institute Of Technology | Nanodispositif de biodétection |
| US20100256518A1 (en) | 2009-04-01 | 2010-10-07 | Yu Chris C | Micro-Devices for Biomedical Applications and Method of Use of Same |
| DE102009016712A1 (de) * | 2009-04-09 | 2010-10-14 | Bayer Technology Services Gmbh | Einweg-Mikrofluidik-Testkassette zur Bioassay von Analyten |
| US10105317B2 (en) | 2009-07-07 | 2018-10-23 | Anpac Bio-Medical Science Co., Ltd. | Method of drug delivery |
| US8828246B2 (en) | 2010-02-18 | 2014-09-09 | Anpac Bio-Medical Science Co., Ltd. | Method of fabricating micro-devices |
| BR112012033783B1 (pt) * | 2010-06-30 | 2021-02-09 | Anpac Bio-Medical Science Co., Ltd. | aparelho de detecção |
| JP5917522B2 (ja) | 2010-09-17 | 2016-05-18 | チャング ヘ バイオ−メディカル サイエンス（ヤンジョウ）カンパニー リミテッド | 生物医学的用途のマイクロデバイス及びその使用 |
| CN103314294B (zh) | 2010-10-05 | 2016-02-03 | 昌微系统科技(上海)有限公司 | 疾病检测器件 |
| WO2012151501A2 (fr) * | 2011-05-05 | 2012-11-08 | Anpac Bio-Medical Science Co., Ltd. | Appareil de détection de cellules tumorales |
| TWI618932B (zh) * | 2012-03-08 | 2018-03-21 | 上海新申派科技有限公司 | 用於改進疾病檢測的微器件 |
-
2013
- 2013-07-15 TW TW102125269A patent/TWI630385B/zh active
- 2013-07-15 TW TW109136751A patent/TW202109037A/zh unknown
- 2013-07-15 TW TW107120050A patent/TWI711819B/zh active
- 2013-07-16 CA CA2879399A patent/CA2879399C/fr active Active
- 2013-07-16 EP EP13819257.0A patent/EP2872887A4/fr not_active Withdrawn
- 2013-07-16 CN CN201380038174.0A patent/CN104508480B/zh active Active
- 2013-07-16 US US14/415,489 patent/US20150198586A1/en not_active Abandoned
- 2013-07-16 WO PCT/CN2013/000852 patent/WO2014012356A1/fr active Application Filing
-
2015
- 2015-01-15 ZA ZA2015/00295A patent/ZA201500295B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2872887A1 (fr) | 2015-05-20 |
| CN104508480A (zh) | 2015-04-08 |
| TW201423097A (zh) | 2014-06-16 |
| TW202109037A (zh) | 2021-03-01 |
| WO2014012356A1 (fr) | 2014-01-23 |
| CA2879399A1 (fr) | 2014-01-23 |
| EP2872887A4 (fr) | 2016-07-27 |
| US20150198586A1 (en) | 2015-07-16 |
| TWI630385B (zh) | 2018-07-21 |
| CN104508480B (zh) | 2017-11-14 |
| ZA201500295B (en) | 2016-09-28 |
| TW201835562A (zh) | 2018-10-01 |
| TWI711819B (zh) | 2020-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2879399C (fr) | Dispositifs et procedes de detection et d'identification ameliorees de maladies | |
| AU2019226260B2 (en) | Methods and apparatus for enhanced detection of diseases | |
| Liu et al. | SERS substrate fabrication for biochemical sensing: Towards point-of-care diagnostics | |
| Liu et al. | Electrochemical/visual microfluidic detection with a covalent organic framework supported platinum nanozyme-based device for early diagnosis of pheochromocytoma | |
| Shi et al. | Modern microfluidic approaches for determination of ions | |
| Kong et al. | Dual-responsive ratiometric fluorescence detection of Ce4+ and ascorbic acid by regulating oxidase-mimicking activity of Ce4+-based nanocomplex | |
| CN104034711A (zh) | 一种利用石墨烯量子点探针检测重铬酸钾的方法 | |
| CN106198694B (zh) | 一种基于裸玻碳电极检测盐酸阿霉素的比率双信号电化学传感器 | |
| Quarin et al. | Recent advances towards point-of-care applications of surface-enhanced raman scattering sensing | |
| Fiel et al. | Recent advances on the electrochemical transduction techniques for the biosensing of pharmaceuticals in aquatic environments | |
| Dong et al. | A “traffic light” signal ratiometric fluorescence sensor for highly sensitive and selective detection of dopamine | |
| CN108802145A (zh) | 一种检测甲胎蛋白的电化学生物传感器及其制备方法 | |
| Jose et al. | Fabrication of anchored complexes as electrodes for sensing heavy metal ions by electrochemical method | |
| Liu et al. | Gold nanomaterials: Important vectors in biosensing of breast cancer biomarkers | |
| Thomas et al. | Biosensors in the Field of Dentistry | |
| Rusling et al. | Low Cost 3D-Printed Biosensor Arrays for Protein-based Cancer Diagnostics based on Electrochemiluminescence. | |
| Liu et al. | Much Stronger Chemiluminescence of 9-Mesityl-10-methylacridinium Ion than Lucigenin at Neutral Conditions for Co2+ Detection | |
| Panhwar et al. | Electroanalytical application of quantum dots in microchips | |
| Fadhil et al. | Recent Advances in Fluorescent Biosensor: A Comprehensive Review | |
| Yuan et al. | Distance-based qualitative determination of pyrophosphate ions with a Haus-made microfluidic paper-based device using the metal–organic framework NH2-MIL-88 (Fe) | |
| KR20240094777A (ko) | 생물학적 분석물의 성분 검출을 위한 효소-기질 반응 기반의 바이오센서 및 이를 이용한 검출방법 | |
| Meng et al. | Robust and ultrasensitive electrochemical detection of ochratoxin a using a highly reactive DNAzyme wired via primer exchange reaction | |
| Sun et al. | Nanopore single molecule ATP detection based on the dual effects of specific capturing and signal amplification | |
| Shalannanda et al. | Biosensors for therapeutic drug monitoring: a review | |
| Parihar et al. | Future potential of SERS-based advanced diagnosis in real-life conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150116 |